Introduction {#s1}
============

Cortical microcircuit function relies on the coordinated activity of a variety of GABAergic interneuron subtypes, which play critical roles in controlling the firing rate of glutamatergic pyramidal neurons, synchronizing network rhythms and regulating behavioral states ([@bib10]; [@bib17]; [@bib25]; [@bib36]; [@bib37]; [@bib38]; [@bib42]; [@bib50]). Different subtypes of cortical interneurons (INs) emerge during development and their specification arises through the complex interaction of cell-intrinsic mechanisms and cell-extrinsic cues ([@bib4]; [@bib14]; [@bib21]; [@bib26]). Cortical INs are generated in a variety of subpallial regions and the combinatorial expression of transcription factors (TFs) in these domains is believed to play a critical role in their fate specification ([@bib26]; [@bib1]; [@bib15]; [@bib48]). The largest fraction (about 60--70%) of cortical INs is generated from NKX2.1-expressing progenitors located in the medial ganglionic eminence (MGE) ([@bib7]; [@bib49]) and their specification is under the control of the TFs LHX6 ([@bib13]; [@bib28]) and SOX6 ([@bib3]; [@bib5]). MGE-derived INs develop into fast-spiking parvalbumin (PV)+ basket and chandelier cells, as well as into Martinotti and multipolar somatostatin (SST)+ INs ([@bib7]; [@bib49]; [@bib13]; [@bib6]; [@bib16]; [@bib45]). The second largest fraction of cortical INs arises from the caudal ganglionic eminence (CGE) ([@bib30]; [@bib33]) and expresses TFs such as PROX1, SP8 and NR2F2 ([@bib9]; [@bib29]; [@bib31]; [@bib40]). CGE-derived INs also express the ionotropic serotonin receptor 3A (5-HT~3A~R) and give rise to a large diversity of INs, including reelin+ cells, vasointestinal peptide (VIP)+/calretinin+ bipolar cells and VIP+/cholecystokinin+ basket cells ([@bib30]; [@bib2]; [@bib39]; [@bib27]; [@bib32]; [@bib46]). Finally, lineage-tracing experiments using *Hmx3 (Nkx5.1)*-Cre ([@bib19]) and *Dbx1*-Cre driver lines ([@bib18]) have shown that a small fraction (about 10%) of cortical INs originate from the preoptic area (POA) ([@bib19]; [@bib18]).

Among cortical INs, neurogliaform cells (NGCs) display unique characteristics. They represent the main source of 'slow' cortical inhibition by acting on metabotropic GABA~B~ receptors ([@bib44]), and are thought to be key effectors of a powerful inhibitory circuit recruited by long-range connections such as interhemispheric and thalamic projections ([@bib11]; [@bib35]; [@bib12]). Whether the current description of NGCs captures an IN subtype related to a distinct developmental specification process is unclear. Here we used in vivo genetic lineage-tracing to follow the developmental origin and trajectory of NGCs. We found that they originate from a distinct pool of 5-HT~3A~R-expressing *Hmx3+* cells located in the rostral POA region, ventrally to the anterior commissure. In the embryonic POA, *Htr3a-*GFP+ INs in the *Hmx3+* domain expressed CGE-enriched TFs such as PROX1 and NR2F2, but only rarely, if not, MGE-related TFs such as NKX2.1 or LHX6. In the cortex, *Hmx3*-derived *Htr3a-*GFP+ INs expressed markers of CGE-derived INs such as NPY and/or reelin, as well as CGE-enriched TFs such as SP8, NR2F2 and PROX1, but neither MGE-specific markers such as PV or SST nor TFs such as LHX6 or SOX6. Finally, single-molecule *in situ* hybridization and electrophysiological recordings followed by *post hoc* reconstructions indicated that *Hmx3*-derived *Htr3a-*GFP+ cells exhibited the molecular, electrophysiological and morphological profile of NGCs. Taken together, these results demonstrate that cortical NGCs have a precise developmental trajectory that is linked to the expression of the transcription factor (TF) *Hmx3* in a discrete embryonic subpallial region.

Results {#s2}
=======

To determine whether the POA could contribute to *Htr3a*-GFP INs, we crossed *Htr3a-*GFP; *R26R-*tdTOM*^fl/fl^* mice with *Hmx3*-Cre mice, a reporter line previously shown to fate map a population of cortical INs derived from cells located in the POA ([@bib19]). Examination of brains from *Hmx3*-Cre::*Htr3a-*GFP; *R26R-*tdTOM*^fl/fl^* matings at embryonic age 14.5 (E14.5) revealed a large fraction of *Hmx3*; tdTOM+ cells co-labelled with *Htr3a-*GFP (85.2 ± 0.9%; 1675/1986 cells in the overlap zone) in a restricted region of the POA, located ventrally to the anterior commissure ([Figure 1A,C](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Individual co-labelled *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells displaying migratory profiles were observed at more caudal levels entering the CGE ([Figure 1B](#fig1){ref-type="fig"}), suggesting that a fraction of *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells migrate from the POA into the CGE. *In situ* hybridization indicated that the vast majority (95.8 ± 0.9%; 115/120 cells) of *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells located in the POA expressed the endogenous *Htr3a* mRNA, in contrast to *Hmx3*; tdTOM+cells negative for *Htr3a*-GFP (0.5 ± 0.5%; 1/158 cells) ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). In addition, a large fraction of *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells in the POA expressed the TFs PROX1 (54.0 ± 2.2%; 249/463 cells) and NR2F2 (65.9 ± 1.3%; 795/1212 cells), which have previously been shown to be enriched in CGE-derived INs ([@bib9]; [@bib29]; [@bib31]; [@bib40]), but more rarely the TF NKX2.1 (15.3 ± 1%; 175/1146 cells) ([Figure 1E,F](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Collectively, these results indicate that a fraction of *Hmx3+* cells located in the POA express the 5-HT~3A~R and a pattern of TFs related to CGE-derived INs.

![A fraction of 5-HT~3A~R-expressing interneurons (INs) originates from *Hmx3*-derived cells in the preoptic area (POA) and expresses transcription factors related to the caudal ganglionic eminence (CGE).\
(**A**) At E14.5, tdTOM specifically labels cells expressing *Hmx3* (*Hmx3*; tdTOM+). *Htr3a*-GFP+ INs co-label with tdTOM in a rostral region of the POA (dashed lines; high magnified images) located ventrally to the anterior commissure (AC). (**B**) At more caudal levels, *Hmx3*; tdTOM+/*Htr3a*-GFP+ embryonic cells appear to further migrate caudally (arrowhead) towards the CGE. High magnified images show *Hmx3*; tdTOM+/*Htr3a*-GFP+ cells entering the ventral CGE (dashed lines). (**C**) More than 80% of *Hmx3*; tdTOM+ cells co-label with *Htr3a*-GFP (and conversely) in the overlap zone (orange dashed line) of the POA domain defined by *Hmx3*; tdTOM recombination (white dashed line). (**D**) *In situ* hybridization showing that almost all *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs in the POA express the *Htr3a* mRNA (arrowheads; yellow outline), whereas *Hmx3*; tdTOM+ cells do not (empty arrowheads; cyan outline). (**E**) In the overlap zone of the POA, IHC reveals that *Hmx3*; tdTOM+/*Htr3a*-GFP+ embryonic cells express (arrowheads) the CGE-enriched transcription factors PROX1 (left) and NR2F2 but not SP8 (right). (**F**) By contrast, the vast majority of *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs do not express NKX2.1 (arrowheads). dTh: dorsal thalamus, GP: globus pallidus, LGE: lateral ganglionic eminence, LV: lateral ventricle, MGE: medial ganglionic eminence. Scale bars: 300 µm in A, B: low magnified images; 100 µm in C, D: low magnified images; 50 µm in A, B: high magnified images; 25 µm in E, F; 10 µm in D: high magnified images.\
10.7554/eLife.32017.004Figure 1---source data 1.Detailed counts of cells quantified in [Figure 1](#fig1){ref-type="fig"} in the different experimental conditions.](elife-32017-fig1){#fig1}

To determine whether *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells in the POA eventually give rise to a specific subpopulation of cortical INs, we examined brains at various postnatal ages. From P5 to P21, *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs were found distributed preferentially in superficial cortical layers and in a variety of other brain regions including in the hippocampus ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells were rarely observed at postnatal ages in the subpallial brain regions corresponding to the embryonic POA (i.e., the preoptic nuclei) ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). *In situ* hybridization for *Htr3a* mRNA indicated that *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells expressed the *Htr3a* transcript, similarly to *Htr3a-*GFP+ cells negative for *Hmx3*; tdTOM ([Figure 2C](#fig2){ref-type="fig"}). About half (51.9 ± 2.1%; 863/1653 cells) of *Hmx3*-derived cells in the cortex were co-labelled with *Htr3a-*GFP+ and virtually all *Hmx3*; tdTOM+/*Htr3a-*GFP+ (96.1 ± 0.5%; 357/372 cells) were positive for the neuronal marker NeuN ([Figure 2D,E](#fig2){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). In contrast, the fraction of *Hmx3*; tdTOM+ cells negative for *Htr3a-*GFP mostly did not express NeuN (3.4 ± 1.3%; 28/758 cells) ([Figure 2D,E](#fig2){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}), and remained relatively constant across postnatal ages ([Figure 2---figure supplement 3A](#fig2s3){ref-type="fig"}, [Figure 2---figure Supplement 3---source data 1](#fig2s3sdata1){ref-type="supplementary-material"}). These cells displayed the morphology of glial cells and expressed the astrocytic markers GFAP and S100β as well as the oligodendrocytic marker SOX10 ([Figure 2---figure supplement 3B--D](#fig2s3){ref-type="fig"}). Overall, these findings indicate that the cortical *Hmx3*-derived lineage observed in the POA differentiate into INs that are *Htr3a-*GFP+, glial cells that are *Htr3a-*GFP negative and, for a small fraction, to NeuN+ neurons negative for *Htr3a*-GFP.

![During the postnatal period, *Hmx3*-derived cells from the preoptic area ([@bib19]) constitute a small but persistent fraction of 5-HT~3A~R-expressing interneurons (INs) ([@bib27]) in superficial cortical layers.\
(**A--B**) *Hmx3*; tdTOM+/*Htr3a*-GFP+ cells represent a fraction of *Htr3a*-GFP+ INs that increases along postnatal ages P5 (left), P9 (middle) and P21 (right). Note that double-labeled cells (open arrowheads) are mainly located in superficial cortical layers. (**C**) *In situ* hybridization showing that, at P21, *Htr3a* mRNA is found in cortical *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs (arrowheads) as in *Htr3a*-GFP+ INs (open arrowheads). (**D--E**) *Hmx3*; tdTOM+/*Htr3a*-GFP+ cells largely express the neuronal marker NeuN (arrowheads) whereas those negative for *Htr3a*-GFP only rarely do (arrows, open arrowhead). Scale bars: 100 µm in A, C: low magnified images; 25 µm in C: high magnified images, D.\
10.7554/eLife.32017.010Figure 2---source data 1.Detailed counts of cells quantified in [Figure 2](#fig2){ref-type="fig"} in the different experimental conditions.](elife-32017-fig2){#fig2}

A second distinct region in the POA expressing *Dbx1* was previously reported to give rise to subsets of cortical INs ([@bib18]). To determine whether a fraction of *Htr3a-*GFP+ INs also originate from *Dbx1*-expressing cells, we examined *Dbx1*-Cre::*Htr3a-*GFP; *R26R-*tdTOM*^fl/fl^* brains at postnatal periods. While the overall contribution of *Hmx3*-derived cells to the *Htr3a-*GFP IN population in the cortex increased with postnatal maturation from P5 (6.8 ± 0.2%; 77/1118 cells) to P21 (16.0 ± 0.3%; 863/5405 cells) ([Figure 3A,C](#fig3){ref-type="fig"}), only minimal fractions (1.44 ± 0.2%; 81/5741 cells at P5; 0.8 ± 0.2%; 20/2551 cells at P21) of *Htr3a-*GFP+ INs were fate-mapped with *Dbx1*; tdTOM ([Figure 3B,C](#fig3){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Moreover, *Dbx1*; tdTOM+ cells were preferentially found in deep cortical layers and expressed the MGE-enriched TF SOX6 (30.4 ± 2.2%; 82/266 cells), while PROX1 was found only in a very small fraction of *Dbx1*; tdTOM+ cells expressing also the *Htr3a-*GFP (2.2 ± 0.7%; 6/266 cells) ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). In addition, *Dbx1*; tdTOM+ INs expressed *Lhx6* mRNA ([Figure 3E](#fig3){ref-type="fig"}), and the MGE-related markers SST and PV ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), and only very rarely the *Htr3a* mRNA ([Figure 3F](#fig3){ref-type="fig"}). Overall, these results indicate that *Hmx3*-derived 5-HT~3A~R+ cortical INs largely originate from *Hmx3*-expressing cells but not from the *Dbx1*+ domain, which gives rise to INs expressing MGE-related markers.

![5-HT~3A~R-expressing interneurons (INs) largely originate from *Hmx3+* but not *Dbx1+* cells.\
(**A--C**) A consistent fraction of cortical *Htr3a*-GFP+ INs co-labels with *Hmx3*; tdTOM (A, arrowheads) at P5 and P21, whereas only a minimal fraction does with *Dbx1*; tdTOM (B, arrowhead). (**D**) *Dbx1*; tdTOM+ INs express the MGE-enriched TF SOX6 (arrowhead) but not the CGE-enriched TF PROX1 (open arrowheads). Only a minimal fraction of *Dbx1*; tdTOM+ co-labelled for *Htr3a*-GFP, among which the majority were PROX1+. (**E--F**) *In situ* hybridization showing that *Dbx1*; tdTOM+ INs express the transcript for the MGE-enriched TF *Lhx6* (E, arrowheads) whereas *Htr3a*-GFP+ INs do not (E, open arrowheads). In contrast, *Dbx1*; tdTOM+ INs do not express the *Htr3a* transcript (F, arrowheads) whereas *Htr3a*-GFP+ INs do (F, open arrowheads). Scale bars: 100 µm in A, B, E, F: low magnified images; 50 µm in A, B, D, E, F: high magnified images.\
10.7554/eLife.32017.013Figure 3---source data 1.Detailed counts of cells quantified in [Figure 3](#fig3){ref-type="fig"} in the different experimental conditions.](elife-32017-fig3){#fig3}

We next examined whether *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells expressed distinct patterns of TFs involved in cortical IN subtype specification. At P21, we found that, similarly to *Htr3a-*GFP+ INs, a large fraction (65.8 ± 3.4%; 202/308 cells) of *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs expressed the CGE-enriched but not the MGE-related TFs. Indeed, a large fraction of them (65.8 ± 3.4%; 202/308 cells) expressed PROX1[[[ ]{.ul}]{.ul}]{.ul}but not SOX6 ([Figure 4A,B](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}), as well as NR2F2 (32.7 ± 5.9%; 71/218 cells), SP8 (9.8 ± 2.6%; 22/218 cells), and both SP8 and NR2F2 (8.8 ± 2.0%; 18/218 cells) ([Figure 4C,D](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). The fraction of *Hmx3*; tdTOM+/*Htr3a-*GFP+ expressing at least one of these two latter TFs was smaller and biased toward NR2F2 expression, when compared to *Htr3a-*GFP+ INs ([Figure 4D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). These findings indicate that *Hmx3*; tdTOM+/*Htr3a-*GFP+ cortical INs express a repertoire of TFs related to CGE but not to MGE-derived INs.

![*Hmx3*; tdTOM+/*Htr3a*-GFP+ cortical interneurons (INs) express markers related to the CGE but not to the MGE.\
(**A--B**) *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs express the CGE-enriched TF PROX1 (A; arrowheads) but not the MGE-related TF SOX6 (A; open arrowheads) similarly to *Htr3a*-GFP+ INs that do not derive from *Hmx3*+ cells (B, right graph). (**C--D**) *Hmx3*; tdTOM+/*Htr3a*-GFP+ cells express the CGE-enriched TFs NR2F2 (arrowheads) and (open arrowheads)/or SP8 (arrow). *Htr3a*-GFP+ derived from *Hmx3*+ cells are biased towards NR2F2 expression, in comparison to *Htr3a*-GFP+ INs that do not co-label with *Hmx3*; tdTOM (D, blue bars). Scale bars: 100 µm in A, C: low magnified images; 50 µm in A, C: high magnified images.\
10.7554/eLife.32017.016Figure 4---source data 1.Detailed counts of cells quantified in [Figure 4](#fig4){ref-type="fig"} in the different experimental conditions.](elife-32017-fig4){#fig4}

We next examined whether *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs expressed classical CGE markers such as reelin, NPY and VIP ([@bib27]; [@bib32]; [@bib46]). Quantification across layers revealed that a large fraction of *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs expressed reelin or NPY. This was particularly striking in layer 1 (L1) for reelin ([Figure 5A,C](#fig5){ref-type="fig"}) and in L2--6 for NPY ([Figure 5B,E](#fig5){ref-type="fig"}), respectively ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Overall, *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs accounted for approximately a third of all reelin+/*Htr3a-*GFP+ INs (34.5 ± 2.3%; 267/797 cells) and of all NPY+/*Htr3a-*GFP+ INs (27.7 ± 2.3%; 149/571 cells) ([Figure 5D,F](#fig5){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Given that INs expressing reelin have been shown to co-express NPY ([@bib27]), we assessed reelin and NPY co-expression in *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells. At P21, only a small fraction (8.0 ± 0.9%; 17/232 cells) of these cells expressed NPY without reelin, thus indicating that reelin labels the largest fraction (66.1 ± 8.6%; 267/398 cells) of *Hmx3*-derived *Htr3a-*GFP+ INs ([Figure 5G,H](#fig5){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). In contrast, *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs did not co-label nor with the CGE-specific marker VIP ([Figure 5I](#fig5){ref-type="fig"}) neither with the MGE-enriched markers SST and PV ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). These results indicate that *Hmx3*-derived *Htr3a-*GFP+ INs mainly belong to the reelin but not to the VIP subtypes and account for an important fraction of all reelin+/*Htr3a-*GFP+ INs.

![*Hmx3*; tdTOM+/*Htr3a*-GFP+ cortical interneurons (INs) express reelin and NPY but not VIP.\
(**A--F**) *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs are stained with the neurochemical markers reelin (A, arrowheads) and NPY (B, arrowheads) as well as *Htr3a*-GFP+ cells negative for *Hmx3*; tdTOM (open arrowheads). Note that reelin-positive *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs are preferentially found in L1-3 (**C**) whereas NPY-expressing *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs are mainly found in L2-6 (**E**). *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs account for more than one third of all reelin-positive *Htr3a*-GFP+ (**D**) and of all NPY-positive *Htr3a*-GFP+ cells (**F**). (**G--H**) *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs mainly express reelin (G, arrowheads) or reelin and NPY (G, open arrowheads) but to a smaller extend only NPY (G, arrow). (**I**) *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs do not express VIP (arrowheads), whereas *Htr3a*-GFP+ INs negative for *Hmx3*; tdTOM do (open arrowheads). WM: white matter. Scale bars: 100 µm in A, B: low magnified images; 50 µm in A, B: high magnified images, G, I.\
10.7554/eLife.32017.019Figure 5---source data 1.Detailed counts of cells quantified in [Figure 5](#fig5){ref-type="fig"} in the different experimental conditions.](elife-32017-fig5){#fig5}

Two distinct profiles of reelin-expressing INs have been identified in L1 of the neocortex, namely neurogliaform (NGCs) and single bouquet-like cells (SBCs) ([@bib8]; [@bib22]). At a molecular level, NGCs are strongly enriched in the carbonic anhydrase 4 (*Car4*) transcript in contrast to SBCs ([@bib8]). Using single-molecule fluorescent *in situ* hybridization experiments ([@bib47]), we found that *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs in L1 exhibited significantly higher levels of *Car4* transcripts in contrast to *Htr3a*-GFP+ INs ([Figure 6A](#fig6){ref-type="fig"}, [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}), thus indicating that *Hmx3*-derived *Htr3a*-GFP+ INs share the molecular profile of NGC. To further verify whether their morphological and electrophysiological features could fit with NGCs, we performed whole-cell recordings ([Figure 6B](#fig6){ref-type="fig"}) and reconstructions ([Figure 6C,D](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) of *Hmx3*-derived versus non *Hmx3*-derived *Htr3a-*GFP+ INs in L1 of the barrel cortex. There, *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs displayed the characteristic morphology of elongated NGCs with dense axonal ramifications mostly restricted to L1 ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), whereas *Htr3a-*GFP+ INs negative for tdTOM had the morphology of SBCs with less developed axonal processes that extended deeper in cortical layers ([Figure 6D](#fig6){ref-type="fig"}). With regard to their first action potential (AP) at rheobase, NGCs are reported to display a type 1 profile with only an after-hyperpolarization potential (AHP), whereas SBCs show a type 2 profile consisting of an AHP followed by an after-depolarization potential (ADP) ([@bib8]; [@bib22]). Strikingly, all (29 out of 29) recorded *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs were of type 1, thus confirming their NGC identity. Moreover, the vast majority of them (23 out of 29) were of type 1A with a deep and wide AHP and only a few (6 out of 29) were of type 1B with a shallow and narrow AHP ([Figure 6E](#fig6){ref-type="fig"}, left, [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). *Htr3a-*GFP+ INs negative for *Hmx3*; tdTOM had more variable profiles, but the majority of them (24 out of 28) were displaying a type two profile with an average ADP amplitude of 2.30 ± 0.51 mV, suggesting that they were SBCs. Most of them (20 out of 28) were of type 2B with a small ADP below the spike threshold, a few others (4 out of 28) were of type 2A with a big ADP above the spike threshold ([Figure 6E](#fig6){ref-type="fig"}, right, [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}) and another few of them (4 out of 28) had not measurable ADP (not shown). *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs showed also a higher tendency to late-spiking when compared to *Htr3a-*GFP+ INs ([Figure 6F](#fig6){ref-type="fig"}, [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs had bigger AP delay average, but not significantly different from *Htr3a-*GFP+ INs negative for *Hmx3*; tdTOM ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}, [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). However, the variability of individual cell values was higher for *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs, indicating that these cells tend to be more late-spiking, a characteristic of NGCs ([@bib8]; [@bib22]). Alignement of the first APs at rheobase revealed other putative differences between the two groups ([Figure 6G](#fig6){ref-type="fig"}, [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). After quantification, *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs significantly differed from *Htr3a-*GFP+ INs negative for *Hmx3*; tdTOM in the first AP amplitude (Peak), AHP amplitude (AHP), membrane resistance (Rm) ([Figure 6H](#fig6){ref-type="fig"}, [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}) and threshold potential (Vthr) ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}). We next aimed to determine whether *Hmx3* and non *Hmx3*-derived *Htr3a-*GFP+ INs classes in L1 could be predicted from single-cell electrophysiological properties. Using an automatic cell type classifier based on combined electrophysiological measures, we were able to predict the *Hmx3*-derived class with 80.7% accuracy, with highest weights found on ADP, Peak and AHP but not Vthr ([Figure 6I,J](#fig6){ref-type="fig"}; [Figure 6---figure supplement 2A,B](#fig6s2){ref-type="fig"}, [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). Finally, we analysed *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs in other cortical layers to determine whether they displayed the same NGC characteristics. Similarly to L1 cells, *Car4* expression in L2-6 was significantly higher in *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs as compared to *Htr3a*-GFP+ INs negative for tdTOM ([Figure 6---figure supplement 3A,B](#fig6s3){ref-type="fig"}, [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). Morphological recovery of *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs located in L2--6 revealed that all cells (7 out of 7) had also the characteristic morphology of NGCs ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). Furthermore, characteristic properties of NGC like the tendency to late spiking, the depth of AHP, and the level of Vthr were significantly more pronounced in these cells compared to L1 cells ([Figure 6---figure supplement 3C,E](#fig6s3){ref-type="fig"}). Overall, these data indicate that *Htr3a-*GFP+ INs displaying the molecular, morphological and electrophysiological properties of NGC INs originate from *Hmx3*-expressing cells in the embryonic POA ([Figure 7](#fig7){ref-type="fig"}, orange), whereas SBCs in layer 1, as well as VIP +INs, are more likely to originate from the CGE ([Figure 7](#fig7){ref-type="fig"}, green).

![*Hmx3*; tdTOM+/*Htr3a*-GFP+ cortical interneurons (INs) in layer 1(L1) display the molecular, morphological and electrophysiological features of neurogliaform cells (NGCs).\
(**A**) RNAscope multiplex fluorescent hybridization for *tdTOM*, *GFP* and *Car4* transcripts on P30 brains showing that L1 *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs express *Car4* at significantly higher levels (orange outline) as compared to *Htr3a*-GFP+ INs negative for tdTOM (green outline) (\*\*\*p\<0.0001; Mann-Whitney test). (**B**) Example of a L1 *Hmx3*; tdTOM+/*Htr3a*-GFP+ cell (arrowhead) or *Htr3a*-GFP+ INs negative for tdTOM (open arrowheads) checked before patching (left image). Example of a patched *Hmx3*; tdTOM+/*Htr3a*-GFP+ IN (middle and right images, arrowhead). (**C**) Illustrative reconstruction of a *Hmx3*; tdTOM+/*Htr3a*-GFP+ IN in L1 displaying the characteristic morphology of an elongated NGC with dense axonal ramifications restricted to L1. (**D**) Illustrative reconstruction of a *Htr3a*-GFP+ IN negative for tdTOM in L1 displaying the characteristic morphology of single bouquet-like cell (SBC) with axonal ramifications extending deep into L5. (**E**) Illustrative traces from recorded *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs (orange) and *Htr3a*-GFP+ INs negative for tdTOM (green), showing the first action potentials (APs) at rheobase and trains of APs at higher current injections. (**F**) Superimposed single AP traces at rheobase of all *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs (orange) and *Htr3a*-GFP+ INs negative for tdTOM (green). Thick traces correspond to type 1A and type 2A examples in E. (**G**) Same traces as in (**F**), aligned to the AP, with a lower time scale. Thin lines are individual cell traces and thick lines are trace averages. The average traces on the right are aligned to the threshold potential (Vthr). (**H**) Plots of AP peak amplitude (Peak; \*\*\*p\<0.0001; unpaired t-test), after hyperpolarization potential amplitude (AHP; \*\*\*p\<0.0001; unpaired t-test) and membrane resistance (Rm; \*p=0.0318; Mann-Whitney test) showing significant differences between the two cell types. (**I**) Absolute linear weights assigned by the classification model trained on all cells with standardized electrophysiological properties. (**J**) Prediction probabilities estimated by the classifier on the cell left out in the leave-one-out-cross-validation (LOOCV) loop. Cells are ordered on the x-axis by origin and prediction value, and the color code reflect their origin. Cells above the probability threshold 0.5 are more likely to be *Hmx3*-derived according to the model. Scale bars: 10 µm A; 20 µm in B; 100 µm C, D.\
10.7554/eLife.32017.025Figure 6---source data 1.Detailed counts of cells expressing *Car4* quantified in [Figure 6](#fig6){ref-type="fig"} in the different experimental conditions.\
10.7554/eLife.32017.026Figure 6---source data 2.Electrophysiological properties of cells quantified in [Figure 6](#fig6){ref-type="fig"}.](elife-32017-fig6){#fig6}

![Developmental origin of cardinal classes of cortical interneurons.\
The Martinotti somatostatin (SST) cell, the parvalbumin (PV) basket cell and the PV+ chandelier cell originate from NKX2.1+ progenitors of the medial ganglionic eminence (MGE, blue) and rely on the transcription factors (TFs) LHX6 and SOX6. The *Htr3a*-GFP/reelin (RELN) single-bouquet cell (SBC), the *Htr3a*-GFP/vasointestinal peptide (VIP)/cholecystokinin (CCK) basket cell and the *Htr3a*-GFP/VIP/calretinin (CR) bipolar cell are derived from cells located in the caudal ganglionic eminence (CGE, green) that express the TFs PROX1, NR2F2 and SP8. The RELN/*Car4*/*Htr3*a-GFP neurogliaform cell (NGC) is specifically derived from *Hmx3*+ cells located in the preoptic area (POA, orange) and express the TFs PROX1 and NR2F2.](elife-32017-fig7){#fig7}

Discussion {#s3}
==========

Distinct subtypes of local GABAergic INs are required to regulate microcircuit function ([@bib10]; [@bib17]; [@bib25]; [@bib36]; [@bib37]; [@bib38]; [@bib42]; [@bib50]). Whether current classifications of cortical IN subtypes relate to intrinsic biological processes such as their developmental specification is a key question in the field ([@bib21]; [@bib45]). Among cortical INs, NGCs are considered as belonging to a distinct subtype acting as a main effector of a powerful inhibitory motif recruited by long-range connections ([@bib44]; [@bib11]; [@bib35]). Here we aimed to track the developmental trajectory of NGCs using genetic fate mapping strategies. We find that NGCs derive from *Htr3a*-GFP+/*Hmx3*+ cells located in the embryonic POA, but not from *Dbx1+* cells. Strikingly, L1 *Hmx3*-derived *Htr3a*-GFP+ INs display the distinct molecular, morphological and electrophysiological properties of NGCs, whereas *Htr3a*-GFP+ INs negative for *Hmx3 *have the profile of SBCs ([@bib8]). *Hmx3*-derived *Htr3a*-GFP+ NGCs represent about a third of reelin-expressing *Htr3a*-GFP+ INs. At a molecular level, *Hmx3*; tdTOM+/*Htr3a*-GFP+ NGCs express CGE-related TFs such as NR2F2 and PROX1, indicating that they share common features with CGE-derived INs. Overall, these results indicate that cortical NGCs derive from a discrete embryonic area located in the subpallial POA and that their specification is linked to the expression of the TF *Hmx3*.

*Htr3a*-GFP+ INs derived from *Hmx3+* cells express CGE-enriched transcription factors {#s3-1}
--------------------------------------------------------------------------------------

Here, we find that a fraction (about 15%) of *Htr3a*-GFP+ cortical INs originate from *Hmx3*+ but not *Dbx1*+ cells in the POA. The overall fraction of *Hmx3*; tdTOM+/*Htr3a*-GFP+ INs to the total *Htr3a-*GFP+ IN population in the cortex almost doubled from P9 to P21, a period during which neural migration is largely achieved. Given that about 40% of developing cortical INs undergo apoptosis during early postnatal life ([@bib43]) higher levels of programmed cell death in *Htr3a*-GFP+ INs negative for tdTOM could thus account for the relative postnatal increase in the cortical *Hmx3; *tdTOM+/*Htr3a*-GFP+ cell population. Overall, our data support the general view that the differential expression of TFs in progenitor cells originating from distinct subpallial germinal zones controls the specification of cortical IN subtypes ([@bib21]; [@bib26]; [@bib1]; [@bib15]; [@bib19]). A striking example in the field relates to chandelier INs, which have been shown to derive from *Nkx2.1*+ cells produced specifically at late embryonic time-points in a restricted region of the MGE ([@bib45]). Three major germinal zones contribute to the generation of cortical INs, including the MGE, the CGE and the POA ([@bib26]). The majority of cortical IN subtypes (about 60--70%) originates from *Nkx2.1+* progenitors in the MGE and includes fast-spiking PV+ basket INs, chandelier cells and SST+ Martinotti cells. In addition to NKX2.1, sequential expression of the TFs such as LHX6 ([@bib1]; [@bib13]; [@bib28]) and SOX6 ([@bib3]; [@bib5]) controls the specification and migration of MGE-derived IN subtypes. Here we find that *Htr3a*-GFP+ cortical INs originating from *Hmx3*+ cells in the POA do not express MGE-enriched TFs such as LHX6 or SOX6. In the embryonic POA, we observe that only a small fraction of *Hmx3; *tdTOM+/*Htr3a*-GFP+ cells expresses the TF NKX2.1, which has been shown to be strongly expressed in the ventricular zone of the POA ([@bib15]). This could be due to either down-regulation of NKX2.1 in postmitotic *Hmx3; *tdTOM+/*Htr3a*-GFP+ cells as previously observed in migrating MGE-derived INs ([@bib34]) or to the fact that the majority of *Hmx3; *tdTOM+/*Htr3a*-GFP+ cells do not originate from NKX2.1 progenitors. In line with this second possibility, recent genetic fate-mapping experiments using a *Nkx2.1*-ires-Flpo knock-in mouse line did not appear to label INs in L1 ([@bib20]). Overall, further work needs to be done to clarify the precise origin of mitotic cells giving rise to the pool of *Hmx3; *tdTOM+/*Htr3a*-GFP+ cells observed in the embryonic POA. In contrast to the absence of co-localization with MGE-enriched TFs, we find that *Hmx3; *tdTOM+/*Htr3a*-GFP+ INs express TFs such as PROX1 and NR2F2 in the embryonic POA and in the postnatal cortex. PROX1 and NR2F2 have been shown to be expressed in CGE cells and these TFs are maintained in subsets of cortical INs as they mature in the developing cortex ([@bib9]; [@bib29]; [@bib40]; [@bib32]; [@bib24]). Our results thus indicate that the specification of *Hmx3*-derived and CGE-derived *Htr3a*-GFP+ INs shares common transcriptional controls and that the expression of *Hmx3 *in a fraction of *Htr3a*-GFP+ defines the distinct subtype of NGCs. To gain insights on the requirement of *Hmx3 *in the specification of *Hmx3*-derived *Htr3a*-GFP+ NGCs, cell-type specific genetic deletion strategies are needed. Finally, the molecular pathways specifically controlled by *Hmx3* in NGCs remain to be identified.

*Htr3a*-GFP+ INs derived from *Hmx3+* cells express CGE but not MGE-enriched neurochemical markers {#s3-2}
--------------------------------------------------------------------------------------------------

MGE-derived INs express the neurochemical markers PV or SST and are preferentially distributed in lower cortical layers, whereas CGE-derived INs specifically express the 5-HT~3A~R, but not PV or SST, and populate more superficial cortical layers ([@bib14]; [@bib21]; [@bib41]). Using *in situ* hybridization, we confirmed that *Hmx3+* lineage give rise to superficial cortical *Htr3a*-GFP+ INs expressing the *Htr3a* transcript. Reelin, VIP and NPY have been used as neurochemical markers to identify different subtypes of *Htr3a*-GFP+ cortical INs ([@bib27]; [@bib32]; [@bib46]). Expressions of reelin and VIP are mutually exclusive in *Htr3a*-GFP+ INs, whereas a fraction of them is found to co-express reelin and NPY ([@bib27]). Using these markers, we find that *Hmx3*; tdTOM+*/Htr3a*-GFP+ INs express reelin and/or NPY, but not VIP, PV or SST. This is in line with previous results showing that *Hmx3+* INs express NPY and not VIP, PV or SST ([@bib19]). Finally, we find that cortical INs from the *Dbx1*+ domain express the MGE-enriched markers PV or SST and only rarely co-label with *Htr3a*-GFP+ INs. In addition, *Dbx1*-derived cortical INs express the MGE-related TFs SOX6 and LHX6 but not the CGE-enriched TF PROX1. Taken together, our findings thus indicate that *Hmx3+* but not *Dbx1*+ cells give rise to a subpopulation of cortical *Htr3a*-GFP+ INs, which share molecular similarities with CGE but not MGE-derived INs. However, given that both *Hmx3+* and *Hmx3- Htr3a*-GFP+ INs express reelin and/or NPY, these classical neurochemical markers are not sufficient to segregate *Hmx3*- and non*-Hmx3*- derived *Htr3a*-GFP+ IN subtypes.

*Hmx3*-derived *Htr3a*-GFP+ INs display the molecular, morphological and electrophysiological properties of NGCs {#s3-3}
----------------------------------------------------------------------------------------------------------------

Electrophysiological recordings obtained from *Htr3a*-GFP+ INs revealed the existence of many different subtypes of INs ([@bib27]). Recently, electrophysiological and morphological characterization of L1 INs combined to single-cell transcriptomics delineated two main types of INs, namely NGCs and SBCs ([@bib8]). Our findings support this observation and indicate that *Hmx3*-derived *Htr3a*-GFP+ INs exhibit the morphological and electrophysiological signature of NGCs and strongly express *Car4*, a transcript present at high level in NGCs, but not in SBCs. In contrast, *Htr3a*-GFP+ INs in L1 that do not derive from *Hmx3+ *cells, have low levels of *Car4* and display the electrophysiological profile of SBCs. These results indicate that *Htr3a*-GFP+ cortical INs in L1 can be subdivided in two major groups characterized by distinct intrinsic properties and that these subgroups are determined by their sites of origin and the differential expression of the TF *Hmx3*. Finally, we show that all *Hmx3*; tdTOM+/*Htr3a-*GFP+ INs analysed in deeper cortical layers also display molecular, morphological and electrophysiological profiles of NGCs, indicating that the *Hmx3*-Cre line labels NGCs across neocortical layers. *In vivo* studies of the canonical cortical microcircuit have mainly relied on the use of the mutually exclusive SST-, PV- and VIP-Cre driver lines ([@bib10]; [@bib17]; [@bib25]; [@bib36]; [@bib37]; [@bib38]; [@bib42]; [@bib50]) but they do not give access to NGCs. These cells are the main source of 'slow' GABA~B~-receptor mediated inhibition in the neocortex ([@bib44]) and are thought to constitute the core cellular component of a canonical inhibitory circuit in L1 ([@bib11]). NGCs acts through GABA~B~-receptors to inhibit the activity of projection neurons and halt ongoing network activity through dendritic calcium channels ([@bib11]). Long-range interhemispheric inhibition has been shown to be mediated through a GABA~B~-receptor dependent mechanism and it has been proposed that this process requires the recruitment of L1 cortical INs, possibly of the neurogliaform-type ([@bib11]; [@bib35]). However, given the diversity of L1 cortical INs ([@bib8]; [@bib23]) and the lack of molecular tools to specifically target NGCs in vivo, it has so far not been possible to manipulate and interrogate exclusively NGCs in cortical networks. Our findings redefine the *Hmx3*-Cre mice as a valuable tool to specifically investigate the functional contribution of NGCs in the cortical microcircuit motif.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                                                                          Source or reference                                                        Identifiers                                       Additional information
  (species) or\                                                                                                                                                                                                                                                  
  resource                                                                                                                                                                                                                                                       
  -------------------------------------------- ------------------------------------------------------------------------------------ -------------------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  Strain, strain background (*Mus Musculus*)   Tg(Htr3a-EGFP)DH30Gsat (referred as *Htr3a*-GFP)                                     GENSAT Consortium                                                          MGI:3846657                                       Maintained on a C57Bl/6 background

  Strain, strain background (*Mus Musculus*)   *B6.Cg-Gt(ROSA)26Sor^tm14(CAG-tdTomato)Hze^*/J (referred as *R26R*-tdTOM*^fl/fl^*)   The Jackson Laboratory                                                     MGI:104735                                        Maintained on a C57Bl/6 background

  Strain, strain background (*Mus Musculus*)   *Tg(Hmx3-icre)1Kess*                                                                 provided by Oscar Marin                                                    MGI:5566775                                       Maintained on a C57Bl/6 background

  Strain, strain background (*Mus Musculus*)   *Dbx1^tm2(cre)Apie^* (referred as *Dbx1-Cre*)                                        provided by Alessandra Pierani                                             MGI:3757955                                       Maintained on a C57Bl/6 background

  Antibody                                     Anti-GFAP, rabbit polyclonal                                                         Abcam, United Kingdom                                                      ab7260                                            (1:2000)

  Antibody                                     Anti-GFP, rabbit polyclonal                                                          Millipore, Germany                                                         AB3080                                            (1:500)

  Antibody                                     Anti-GFP, goat polyclonal                                                            Abcam                                                                      ab5450                                            (1:2000)

  Antibody                                     Anti-NeuN (clone A60), mouse monoclonal                                              Millipore                                                                  MAB377                                            (1:500)

  Antibody                                     Anti-NKX2.1 (H-190), rabbit polyclonal                                               Santa Cruz Biotechnology, Dallas, TX                                       sc-13040                                          (1:100)

  Antibody                                     Anti-NPY, rabbit polyconal                                                           Abcam                                                                      ab10980                                           (1:500)

  Antibody                                     Anti-NR2F2, rabbit polyclonal                                                        Abcam                                                                      ab42672                                           (1:500) antigen retrieval (Citrate buffer pH 6.0; 85°C; 20 min)

  Antibody                                     Anti-PROX1, goat polyclonal                                                          R&D System,Minneapolis, MN                                                 AF2727                                            (1:250)

  Antibody                                     Anti-PV, mouse monoclonal                                                            Swant, Switzerland                                                         PV235                                             (1:2000)

  Antibody                                     Anti-Reelin, mouse monoclonal                                                        Abcam                                                                      ab78540                                           (1:500)

  Antibody                                     Anti-S100β, rabbit polyclonal                                                        Abcam                                                                      ab41548                                           (1:2000)

  Antibody                                     Anti-SST, rat monoclonal                                                             Millipore                                                                  MAB354                                            (1:500)

  Antibody                                     Anti-SOX6, rabbit polyclonal                                                         Abcam                                                                      ab30455                                           (1:500)

  Antibody                                     Anti-SOX10 (N-20), goat polyclonal                                                   Santa Cruz Biotechnology                                                   sc-17343                                          (1:100)

  Antibody                                     Anti-SP8 (C-18), goat polyclonal                                                     Santa Cruz Biotechnology                                                   sc-104661                                         (1:50) antigen retrieval (Citrate buffer pH 6.0; 85°C; 20 min)

  Antibody                                     Anti-tdTOM, goat polyclonal                                                          Sicgen, Portugal                                                           AB8181-200                                        (1:500)

  Antibody                                     Anti-VIP, rabbit polyclonal                                                          Abcam                                                                      ab22736                                           (1:500) ASCF perfusion; 2 hr PFA 4% postfixation

  Antibody                                     Donkey anti-rabbit Alexa\                                                            Invitrogen, Carlsbad, CA                                                   A21206                                            (1:500)
                                               Fluor488                                                                                                                                                                                                          

  Antibody                                     Donkey anti-goat Alexa\                                                              Invitrogen                                                                 A11055                                            (1:500)
                                               Fluor488                                                                                                                                                                                                          

  Antibody                                     Donkey anti-goat Alexa\                                                              Abcam                                                                      ab175664                                          (1:500)
                                               Fluor405                                                                                                                                                                                                          

  Antibody                                     Donkey anti-rabbit Alexa\                                                            Abcam                                                                      ab175651                                          (1:500)
                                               Fluor405                                                                                                                                                                                                          

  Antibody                                     Donkey anti-rabbit Alexa Fluor647                                                    Invitrogen                                                                 A31573                                            (1:500)

  Antibody                                     Donkey anti-rat Alexa Fluor647                                                       Invitrogen                                                                 A21247                                            (1:500)

  Antibody                                     Donkey anti-mouse Alexa Fluor647                                                     Invitrogen                                                                 A31571                                            (1:500)

  Antibody                                     Donkey anti-goat Alexa Fluor647                                                      Invitrogen                                                                 A21447                                            (1:500)

  Antibody                                     Streptavidin, Alexa Fluor647-conjugated                                              ThermoFisher/Invitrogen                                                    S21374                                            (1:500)

  Antibody                                     Anti-Digoxigenin-AP, Fab fragment                                                    Roche, Switzerland                                                         11082736103                                       (1:2000)

  Recombinant DNA reagent                      *Htr3a* plasmid probe                                                                Gift from Dr. B. Emerit                                                    NA                                                Linearization: HindIII-HF; antisense synthesis: T7; concentration 1 µg

  Recombinant DNA reagent                      *Lhx6* plasmid probe                                                                 Gift from Dr. M. Denaxa                                                    NA                                                Linearization: Not1; antisense synthesis: T3; concentration 1 µg

  Recombinant DNA reagent                      RNAScope Probe-tdTomato-C2                                                           Affimetrix, Santa Clara, CA                                                317041-C2                                         

  Recombinant DNA reagent                      RNAScope Probe-EGFP                                                                  Affimetrix                                                                 400281                                            

  Recombinant DNA reagent                      RNAScope Probe-Car4-C3                                                               Affimetrix                                                                 468421-C3                                         

  Sequence-based reagent                       Genotyping PCR primer for*B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze*/J                Microsynth, Switzerland\                                                   WT-F (oIMR9020): AAG GGA GCT GCA GTG GAG TA       <https://www2.jax.org/protocolsdb/f?p=116:5:0::NO:5:P5_MASTER_PROTOCOL_ID>,P5_JRS_CODE:29436,007909
                                                                                                                                    (desalted;100 µM stock)                                                                                                      

  Sequence-based reagent                       Genotyping PCR primer for*B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze*/J                Microsynth (desalted;100 µM stock)                                         WT-R (oIMR9021): CCG AAA ATC TGT GGG AAG TC       

  Sequence-based reagent                       Genotyping PCR primer for*B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze*/J                Microsynth (desalted;100 µM stock)                                         Mut-R (oIMR9103): GGC ATT AAA GCA GCG TAT CC      

  Sequence-based reagent                       Genotyping PCR primer for*B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze*/J                Microsynth (desalted;100 µM stock)                                         Mut-F (oIMR9105): CTG TTC CTG TAC GGC ATG G       

  Sequence-based reagent                       Genotyping PCR primer for Tg(Htr3a-EGFP)DH30Gsat                                     Microsynth (desalted;100 µM stock)                                         Com-F (273): GCA AGA TGT GAC CAA GCC ACC TAT TT   <http://www.med.unc.edu/mmrrc/resources/genotyping-protocols/mmrrc-273>

  Sequence-based reagent                       Genotyping PCR primer for Tg(Htr3a-EGFP)DH30Gsat                                     Microsynth (desalted; 100 µM stock)                                        WT-R: CAG CCC TCA GCC CTT TGA GAC TTA AG          

  Sequence-based reagent                       Genotyping PCR primer for Tg(Htr3a-EGFP)DH30Gsat                                     Microsynth (desalted; 100 µM stock)                                        Mut-R: TGA ACT TGT GGC CGT TTA CGT CG             

  Sequence-based reagent                       Genotyping PCR primer for*Tg(Hmx3-icre)1Kess*                                        Microsynth (desalted;100 µM stock)                                         Mut-F: CTC TGA CAG ATG CCA GGA CA                 

  Sequence-based reagent                       Genotyping PCR primer for*Tg(Hmx3-icre)1Kess*                                        Microsynth (desalted;100 µM stock)                                         Mut-R: TCT CTG CCC AGA GTC ATC CT                 

  Sequence-based reagent                       Genotyping PCR primer for*Dbx1^tm2(cre)Apie^*                                        Microsynth (desalted;100 µM stock)                                         WT-F (1307): GCA AGG AAA TGT CTC TGG GAC          <https://www.infrafrontier.eu/sites/infrafrontier.eu/files/upload/public/pdf/genotype_protocols/EM01924_geno.pdf>

  Sequence-based reagent                       Genotyping PCR primer for*Dbx1^tm2(cre)Apie^*                                        Microsynth (desalted;100 µM stock)                                         WT-R (1115): GAG GAT GAG GAA ATC ACG GTG          

  Sequence-based reagent                       Genotyping PCR primer for*Dbx1^tm2(cre)Apie^*                                        Microsynth (desalted;100 µM stock)                                         Mut-F (cre83): GTC CAA TTT ACT GAC CGT ACA CC     

  Sequence-based reagent                       Genotyping PCR primer for*Dbx1^tm2(cre)Apie^*                                        Microsynth (desalted;100 µM stock)                                         Mut-R (cre85): GTT ATT CGG ATC ATC AGC TAC ACC    

  Commercial assay or kit                      VECTASTAIN Elite ABC-HRP Kit                                                         VectorLab, Burlingame, CA                                                  PK-6100                                           Manufacturer\'s protocol

  Commercial assay or kit                      DAB Peroxidase (HRP) Substrate Kit (with Nickel), 3,3'-diaminobenzidine              VectorLab                                                                  SK-4100                                           Manufacturer\'s protocol

  Commercial assay or kit                      RNAscope Fluorescence Multiplex Reagent Kit                                          Advanced Cell Diagnostics, Newark, CA                                      320850                                            Manufacturer\'s protocol (fresh frozen tissue)

  Chemical compound, drug                      Nε-(+)-Biotinyl-L-lysine (biocytin)                                                  Sigma Aldrich, Germany                                                     B4261                                             Used at 8.1 mM

  Chemical compound, drug                      Fast Red tablets                                                                     Kem-En-Tech, Denmark                                                       4210                                              Manufacturer\'s protocol

  Chemical compound, drug                      Hoechst 33258                                                                        Sigma Aldrich                                                              23491-45-4                                        (1:10000)

  Chemical compound, drug                      Thiopental Inresa 0.5 g                                                              Inresa Arzneimittel GmbH, Germany                                                                                            Used at 50 mg/kg

  Software, algorithm                          Microsoft Office 2017 (Excel, Word)                                                  © 2017 Microsoft, Redmond, WA                                              v.16.9.1                                          Manuscript editing

  Software, algorithm                          Adobe Suit CC (Photoshop, Illustrator, Acrobat)                                      Adobe Systems, San José, CA                                                v.22.0.1                                          Image treatment, figure editing

  Software, algorithm                          GraphPad Prism                                                                       GraphPad software, Inc., La Jolla, CA                                      v.7.0                                             Statistics, graph editing

  Software, algorithm                          Fiji                                                                                 doi:10.1038/nmeth.2019                                                     v.2.0.0                                           Image editing, manual counting

  Software, algorithm                          EndNote X                                                                            Thomson Reuters, Canada                                                    v.7.7.1                                           Reference editing, bibliography

  Software, algorithm                          Neurolucida v.11.02.1                                                                Microbrightfield, MBF Bioscience, Williston, VT                            v.11.02.1                                         Neuron reconstruction

  Software, algorithm                          Neurolucida Explorer                                                                 Microbrightfield, MBF Bioscience                                           v.11.02.1                                         Morphological reconstruction editing

  Software, algorithm                          MatLab                                                                               MathWorks, Natick, MA                                                                                                        Electrophysiological recordings measurment/editing

  Software, algorithm                          Ephus (MATLAB-based)                                                                 doi: 10.3389/fncir.2010.00100                                              v\. 2.1.0                                         Electrophysiological recordings data aquisition

  Software, algorithm                          Clampfit                                                                             Molecular Devices, San José, CA                                            v\. 10.1.0.10                                     Electrophysiological recordings offline analysis

  Software, algorithm                          R programming language                                                               [www.R-project.org](http://www.R-project.org)                              v\. 3.4.0                                         Statistics

  Software, algorithm                          R package bmrm                                                                       doi:10.1038/ncomms14219                                                    v\. 3.5                                           Prediction model

  Software, algorithm                          NLMorpholoyConverter                                                                 <http://neuronland.org/NLMorphologyConverter/NLMorphologyConverter.html>   v\. 0.8.1                                         Morphological reconstruction editing

  Software, algorithm                          R package NeuroAnatomy Toolbox                                                       doi: 10.1016/j.neuron.2016.06.012                                          v\. 1.8.12.9000                                   Morphological reconstruction editing
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

Animal experiments were approved by the local Geneva animal care committee (GE113/16) and conducted according to international and Swiss guidelines. Mice were housed in the conventional area of the animal facility of the Geneva Medical Center. Water and food were provided *ad libitum* and both temperature (22 ± 2°C) and dark/light cycles (12 hr each) were controlled. Timed-pregnant mice were obtained by overnight mating and the following morning was counted as embryonic day (E) E0.5. *Tg(Htr3a-EGFP)DH30Gsat* mice expressing the enhanced GFP under the control of the *Htr3a* regulatory sequences (*Htr3a-*GFP) were provided by the GENSAT Consortium and maintained on a C57Bl/6 background ([@bib32]). *B6.Cg-Gt(ROSA)26Sor^tm14(CAG-tdTomato)Hze^*/J loxP flanked reporter mice (*R26R-*tdTOM*^fl/fl^*) were obtained from Jackson Laboratory. *Htr3a-*GFP mice were crossed with *R26R-*tdTOM*^fl/fl^* mice to obtain *Htr3a-*GFP; *R26R-*tdTOM*^fl/fl^* mice. *Tg(Hmx3-icre)1Kess* (*Hmx3*-Cre) mice were obtained from Oscar Marin and previously described ([@bib19]). *Dbx1^tm2(cre)Apie^* (*Dbx1-*Cre) mice were obtained from Alessandra Pierani and previously described ([@bib18]). Details of the genotyping procedure are given in the Key Resources Table.

Tissue processing and immunohistochemistry {#s4-2}
------------------------------------------

Pregnant females were euthanized by lethal intraperitoneal (i.p.) injection of pentobarbital (50 mg/kg), embryos were collected by caesarian cut and brains dissected and fixed overnight (O.N.) in cold 4% paraformaldehyde dissolved in 0.1M phosphate buffer (PFA) pH 7.4. For postnatal brains, animals were deeply anesthetized by i.p. injection of pentobarbital and transcardially perfused with 0.9% saline/liquemin followed by cold 4% PFA. Brains were cut on a Vibratome (Leica VT1000S) at 60 µm for immunohistochemistry (IHC) or at 80--100 µm for free-floating *in situ* hybridization (ISH). Sections were kept in a cryoprotective solution at −20°C or processed directly for IHC or ISH as described ([@bib32]). The following primary antibodies were used: rabbit anti-GFAP (1:2000, Abcam), goat anti-GFP (1:2000, Abcam), rabbit anti-GFP (1:500, Millipore), mouse anti-NeuN (1:500, Millipore), rabbit anti-NKX2.1 (1:100, Santa Cruz Biotechnology), rabbit anti-NPY (1:500, Abcam), rabbit anti-NR2F2 (1:500, Abcam), goat anti-PROX1 (1:250, R and D System), mouse anti-Parvalbumin (PV) (1:2000, Swant), mouse anti-Reelin (1:500, Abcam), rabbit anti-S100β (1:2000, Abcam), rat anti-Somatostatin (SST) (1:500, Millipore), rabbit anti-SOX6 (1:500, Abcam), goat anti-SOX10 (1:100, Santa Cruz Biotechnology), goat anti-SP8 (1:50, Santa Cruz Biotechnology), goat anti-tdTomato (tdTOM) (1:500, Sicgen), rabbit anti-VIP (1:500, Abcam). Secondary goat or donkey Alexa-405,--488, −568 and −647 antibodies (Abcam, Invitrogen) raised against the appropriate species were used at a dilution of 1:500 and sections were counterstained with Hoechst 33258 (1:10000) when no Alexa-405 staining was done. A list of the antibodies is given in the Key Resources Table.

*In situ* hybridization and RNAscope {#s4-3}
------------------------------------

Sections were hybridized with the respective DIG-labeled RNA probes as described previously ([@bib32]). The *Htr3a* plasmid probe was linearized with *HindIII-HF* for antisense RNA probe synthesis by T7 polymerase (kind gift from Dr. B. Emerit). The *Lhx6* plasmid probe ([@bib28]) was linearized with Not1 for antisense RNA probe synthesis by T3 polymerase (kind gift from Dr. M. Denaxa). The unbound probe was washed and slices incubated with alkaline phosphatase-conjugated anti-DIG antibody (1:2000, Roche) O.N. at 4°C. Fast Red (Kem-En-Tech) was used as an alkaline phosphatase fluorescent substrate to reveal the hybridized probe. We took advantage of the removal of both GFP and tdTOM endogenous fluorescence due to protocol treatments and revealed them by IHC using green and far-red emitting secondary antibodies, respectively. For illustration purposes, the bound probe (red) and the tdTOM (far red) are shown in blue and red, respectively. For RNAscope experiments, P30 brains were rapidly extracted and fresh frozen. After dehydration and protease treatment, coronal 12 µm-thick brain sections were processed using the RNAscope Multiplex Fluorescent Reagent Kit (Advanced Cell Diagnostics) according to the manufacturer's protocol. Probes targeting mRNAs of the *GFP* and *tdTOM* transgenes and of the endogenous *Car4* gene were designed by Advanced Cell Diagnostics.

Imaging and quantification of interneuron identity and distribution {#s4-4}
-------------------------------------------------------------------

Images were acquired using confocal microscopes (Nikon A1R or Axio Imager.Z2 Basis LSM 800) equipped with oil-immersion 40x, 60x and 63x objectives (CFI Plan Fluor 40x/1.3 and CFI Plan Apo VC H 60x/1.4, Nikon or Plan-APO (UV) VIS-IR 40x/1.4 and Plan-Apochromat f/ELYRA 63x/1.4, LSM). For widefield illustrations ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), images were taken with Axioscan.Z1 slidescanner (Zeiss), equipped with Plan-Apochromat 10x/0.45 objective (Zeiss). Images were lightly treated (gamma, brightness and and despeckle filter only) for visual purpose with Photoshop CC and manual counts were achieved with Fiji. Data are presented as brain averages calculated from at least three slices at different rostro-caudal levels per brain (except for P5 Dbx1 brain 3). A detailed description of the counts, cells and brains in the different experiments is given in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Electrophysiological recordings and morphological tracing {#s4-5}
---------------------------------------------------------

300 µm-thick coronal brain slices were prepared from 3 to 4 weeks old *Hmx3*; tdTOM+/*Htr3a-*GFP+ mice with a vibratome (Leica VT 1000S). In the recording chamber, slices were continuously superfused with ACSF (32°C) containing (in mM): NaCl (119), KCl (2.5), CaCl~2~ (2.5), MgSO~4~ (1.3), NaH~2~PO~4~ (1.0), NaHCO~3~ (26.2), and glucose (22), and equilibrated with 95% O~2~/5% CO~2~, pH 7.4. Whole-cell recordings were obtained from visually identified *Hmx3*; tdTOM+/*Htr3a-*GFP+ in cortical layers 1--6 and *Hmx3*; tdTOM-/*Htr3a-*GFP+ INs in L1, using an upright microscope (Zeiss Axioskop FS) equipped with differential interference contrast and standard epifluorescence. Borosilicate glass patch pipettes had a resistance of 5--6 MΩ when filled with an internal solution containing (in mM): K gluconate (135), KCl (4), HEPES (10), Phosphocreatine (10), Mg-ATP (4), Na-GTP (0.3), and biocytin (8.1). Current clamp recordings were performed at rest and firing properties were studied by delivering consecutive current pulses, 500 ms duration each, ranging from −20 to +360 pA with a 5 pA increment, every 3 s. Data were acquired using a Multiclamp 700B Amplifier (Molecular Devices), and digitized at 10 kHz (National Instruments), using MATLAB (MathWorks)-based Ephus software (Ephus; The Janelia Farm Research Center). Offline analysis was performed using Clampfit (Version 10.1.0.10, Molecular Devices). Cells were accepted for analysis only if their series resistance was below 30 MΩ and did not change more than 20% during recordings. Following patch-clamp recordings, slices were incubated in ACSF for 1--2 hr at room temperature, then fixed overnight with 4% PFA / 2% Glutaraldehyde in 0.1 M phosphate buffer. Biocytin-filled recorded cells were revealed with IHC, using streptavidin-Alexa 647 conjugate (1:500, Thermo Fisher Scientific), and confirmed being in L1 and expressing *Hmx3*; tdTOM and/or *Htr3a-*GFP. For detailed morphology, slices were quenched for endogenous peroxidase activity in methanol/0.5% H~2~0~2~, blocked in 0.05 M Tris buffer pH 7.4/0.6% NaCl/0.3% Triton X-100/10% normal horse serum (NHS) and incubated (O.N., 4°C) with avidin-biotin complex (Vectastain Elite ABC-HRP Kit) in 0.1M Tris buffer pH 7.7. 3,3'-diaminobenzidine (DAB) revelation was performed following the manufacturer's protocol (Vectastain DAB Kit; SK-4100). Slices were finally dehydrated in graded series of ethanol/xylene and mounted in Eukitt (Sigma). Morphological reconstructions of biocytin-filled cells were performed with Neurolucida software (v. 11.02.1, MBF Bioscience, Microbrightfield), linked to a microscope (Nikon eclipse 80i) equipped with an oil-immersion 100x objective (Plan Apo VC/1.4, Nikon). Brightfield images of the reconstructed cells were acquired with the same microscope and a 10x objective (Plan Apo/0.45, Nikon). Traces were extracted with Neurolucida Explorer (v.11.02.1, MBF Bioscience, Microbrightfield). 14 *Hmx3*; tdTOM+/*Htr3a-*GFP+ cells (7 in L1, 5 cells in L2/3 and 2 cells in L5) and 3 *Hmx3*; tdTOM-/*Htr3a-*GFP+ INs (3 in L1) from four brains were recovered for morphology. For L1 cells, border artefacts in morphological tracings due to tissue compression were corrected. Traces from 14 *Hmx3*; tdTOM+/*Htr3a-*GFP+ and 3 *Hmx3*; tdTOM-/*Htr3a-*GFP+ INs from four brains were analysed blindly. The membrane resistance (Rm), the membrane resting potential and five properties of the first action potential (AP) at rheobase - i) threshold potential (Vth); ii) AP amplitude (peak); iii) AP latency from current step onset (delay); iv) after-hyperpolarization potential amplitude (AHP) and when present; v) after-depolarization potential amplitude (ADP) - were measured for all recorded cells. Both electrophysiological features and morphological tracings were analyzed blindly and data were attributed back to their corresponding cell. Values for each recorded cell are provided in [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"} and [Figure 6---figure Supplement 3---source data 1](#fig6s3sdata1){ref-type="supplementary-material"}.

Statistical analysis and prediction model {#s4-6}
-----------------------------------------

Animals were used regardless of their sex and statistical analysis was done with R programming language and GraphPad Prism. No statistics were used to determine optimal group sample size; however, sample sizes were similar to those used in previous publications from our group and others. Normality of the samples was assessed with D'Agostino-Pearson test and when distribution was not normal, non-parametric tests were applied. Using *bmrm* (v3.3) package for L1-regularized logistic regression model, data were standardized, and a L1-regularized logistic regression model was trained to distinguish between *Htr3a*-GFP+ INs that were *Hmx3*-derived and those which were not. This model assigned a linear weight that reflects the power of each feature in the model logistic regression and computed a probability that a given cell is *Hmx3*-derived in such a way that the misclassification error on the training data was minimized ([Figure 6I--J](#fig6){ref-type="fig"}). Classification performance of the L1-regularized logistic regression algorithm was assessed by leave-one-out-cross-validation (LOOCV). It consists in training a model on all but one cell, feeding the model with this isolated cell to predict its origin and finally assessing if the prediction is correct. Looping it over all cells, yields a prediction value for each cell, which is used to estimate the generalization error of the classifier. Finally, in order to determine if the prediction made by the logistic regression model improved over the signal contained into each feature taken individually, receiver operating characteristic (ROC) curves were drawn to visualize the sensitivity/specificity ratio for each feature and for the leave-one-out predictions. Areas under the curves (AUC) were analyzed to determine the strongest signals ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}, [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Neurogliaform cortical interneurons expressing the serotonin receptor 3A originate from the preoptic area\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Joseph Gleeson as the Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The paper by Niquille et al. reports that a specific cortical interneuron type called Neurogliaform (NGFC) comes from an embryonic domain in the mouse brain, called Preoptic Area (POA). The authors perform a careful and quite detailed analysis at different development stages using a variety of tools, which include compact transgenic mouse lines, immunohistochemistry, sensitive in situ hybridization, as well as physiology to prove their point. The techniques are appropriate and the data is of high quality. The most important result of the study is the identification of these interneurons as a population of NGCs, a specific class of cortical interneurons. This is a timely study, as researchers are trying to understand cortical interneuron diversity in general, as well as its developmental origin. Among all the other interneuron types that have been reported, NGFC is probably one of the least studied ones, as to date there are no genetic tools to label and target them. This study puts forth that the *Nkx5.1*Cre BAC transgenic mouse line is that missing tool.

This study is a follow-up of the Gelman DM et al., 2009 and 2011 work, showing that a population of cortical interneurons comes from the POA, as opposed to the MGE or CGE. In the 2009 paper and using the same *Nkx5.1*-Cre BAC mouse line, the authors report that the majority of cells seem to belong a more or less single type of interneuron, based on action potential firing and morphological features, which were consistent with previous functional studies on NGFCs. Nevertheless, in that paper, the authors did not name it NGFC and due to the lack of additional makers that have come up since, did not stain for reelin, *Car4*, NR2F2 or Sp8. In addition the paper did not do a detailed characterization of the passive and active electrophysiological properties of the fate-mapped cells. All three reviewers agree that the manuscript adds substantially to the field of cortical interneuron development, but that still requires additional clarifications/support for its conclusions.

Essential revisions:

[Figure 1](#fig1){ref-type="fig"}: This study relies heavily on two different BAC transgenic lines -- *Nkx5.1*(BAC)-Cre, i.e., *Tg(Hmx3-iCre)1Kess*, and *Htr3a*(BAC)-EGFP, i.e., *Tg(Htr3a-EGFP)DH30Gsat* -- that, like many BAC transgenics, are complicated reagents whose respective expression profiles may not always accurately recapitulate their corresponding genetic loci. The use of *Htr3a*(BAC)-EGFP as a proxy for CGE origin is clearly not straightforward in the E14.5 embryo, e.g., there is robust ectopic EGFP expression evident in the cortical plate ([Figure 1A](#fig1){ref-type="fig"}). The overlap between *Nkx5.1*(BAC)-Cre; Ai14 (\"*Nkx5.1*-tdTom\") and *Htr3a*(BAC)-EGFP (\"*Htr3a-EGFP*\") in the E14.5 POA is convincing, but there is also overlap in the ventral CGE (1B), and because *Nkx5.1* is not expressed in POA progenitors but only in migratory precursors it is difficult to assign a precise location to this lineage\'s origin. Are there *Nkx5.1*-tdTOM+/*Htr3a*(BAC)-EGFP cells that remain in the POA at postnatal ages? If so, it would be difficult to distinguish whether the double positive cells highlighted in [Figure 1A](#fig1){ref-type="fig"} give rise to the cortical interneurons analyzed vs. lineages that remain in the POA. Because *Nkx5.1* is not expressed in progenitors, the absence of overlap with *Nkx2.1* ([Figure 1E](#fig1){ref-type="fig"}) does not prove that these lineages do not arise from an *Nkx2.1*+ territory; in fact, Flames et al. presented evidence (as does [Figure 1E](#fig1){ref-type="fig"}) that *Nkx2.1* is expressed in the entire POA progenitor pool, even though Lhx6 expression is not maintained in POA lineages, in contrast to those arising from the MGE. Recent fate maps using an *Nkx2.1*-Flpo knock in line (vs. the *Nkx2.1*(BAC)-Cre, whose expression was known to be excluded from the *Nkx6.2* territory) show little if any labeling of layer 1 -- this does not prove that layer 1 cells do not arise from the POA, but it puts more weight on the accuracy of the *Nkx5.1*(BAC)-Cre line as a proxy for POA origin. How do the fate maps in this study compare with those shown in Gelman et al. 2009? Has there been any \'drift\' in the recombination mediated by this BAC tg over time?

There are tdTOM+/GFP+ cells in all layers of the neocortex, yet the authors have only characterised the electrophysiological properties of cells in layer 1. Are neurons in other layers also NGCs? Do they express *Car4* and have the characteristic morphology of NGCs? A detailed characterization of these neurons throughout all layers is not expected, but it is important to clarify this point.

Quantifications are also needed for panels 1C-E. In relation to the expression of *Nkx2-1*, this transcription factor is downregulated as cells migrate towards the cortex (Nobrega-Pereira et al., 2008). Previous work that has suggested that NGCs derive from both the MGE and the CGE (Tricoire et al., J Neurosci 2010), so it would be important to determine in the tdTOM+/GFP+ cells studied here derive from *Nkx2-1* progenitor cells in the POA. On that note, the authors should correct the statement that *Nkx2-1* is an MGE-specific transcription factor. This is not correct: *Nkx2-1* is also expressed in the ventricular zone of the POA \[Flames et al., 2007\]). The tdTOM+/GFP+ cells may downregulate *Nkx2-1* by the time they have left the ventricular zone. This is a complicated experiment, because it would probably involve crossing *Nkx2-1*-Flp and *Nkx5.1*-Cre lines with a dual reported, but this is necessary to support the claim \"these results indicate that a fraction of *Nkx5.1*+ progenitors in the POA express 5-HT3AR and a pattern of TFs more related to CGE than to MGE-derived INs\".

The authors should include morphological reconstructions of the axon of tdTOM+/GFP+ cells to reinforce the notion that these cells are indeed NGCs. The axon of these cells is so characteristic that is almost impossible to miss. Another interesting property of NGCs (at least in hippocampus and piriform cortex) is persistent firing that outlasts the injected current (Sheffield et al., Nature Neurosci 2011; Suzuki et al., Front Cell Neurosci 2014). Is this property also observed in S1 tdTOM+/GFP+ cells?

Additional experiments requested by reviewers but not essential. If not performed, at least address in the text:

Since NGFCs have also been reported in other cortical layers, it would be good if the authors recorded the *Htr3a*-GFP and *Nkx5.1*-tdtomato positive fate-mapped cells in other layers besides layer 1. Although beyond the scope of the paper, it would also be very interesting to check the fate-mapped cells in other brain regions the cells have shown to be present, such as the amygdala. The study would be more complete if the authors morphologically reconstructed some cells from several layers (can be combined with point 1) to show that they fit the pattern observed in other studies.

Perform a limited number of paired-recordings between interneurons and pyramidal cells to show that the *Htr3a*-GFP and *Nkx5.1*-tdtomato positive cells have the very characteristic slow GABAA and GABAB receptor -dependent synaptic output of NGFCs and that *Htr3a*-GFP only cells do not. The reviewer does realize that this is a significant and time-consuming task, but if achieved, it would leave very little room for disputes on whether these cells are NGFCs.

10.7554/eLife.32017.034

Author response

> Essential revisions:
>
> [Figure 1](#fig1){ref-type="fig"}: This study relies heavily on two different BAC transgenic lines -- Nkx5.1(BAC)-Cre, i.e., Tg(Hmx3-iCre)1Kess, and Htr3a(BAC)-EGFP, i.e., Tg(Htr3a-EGFP)DH30Gsat -- that, like many BAC transgenics, are complicated reagents whose respective expression profiles may not always accurately recapitulate their corresponding genetic loci. The use of Htr3a(BAC)-EGFP as a proxy for CGE origin is clearly not straightforward in the E14.5 embryo, e.g., there is robust ectopic EGFP expression evident in the cortical plate ([Figure 1A](#fig1){ref-type="fig"}). The overlap between Nkx5.1(BAC)-Cre; Ai14 (\"Nkx5.1-tdTom\") and Htr3a(BAC)-EGFP (\"Htr3a-EGFP\") in the E14.5 POA is convincing, but there is also overlap in the ventral CGE (1B), and because Nkx5.1 is not expressed in POA progenitors but only in migratory precursors it is difficult to assign a precise location to this lineage\'s origin.

In accordance with previous data from the Fishell and Rudy labs (Lee, S. et al., 2010), we also observe EGFP expression in preplate cortical neurons at early embryonic ages in the *Htr3a*(BAC)-EGFP mouse line. We thus agree that the *Htr3a*(BAC)-EGFP mouse line is not a straightforward proxy for CGE-derived cortical interneurons (INs) at embryonic time-points. However, at postnatal ages, the combination of *Htr3a*(BAC)-EGFP and MGE-derived interneuron driver lines has been shown to be a useful tool to track 100% of cortical INs (Lee et al., 2010). Because *Nkx5.1* is not expressed in POA progenitors and only in migratory precursors, we agree that it is currently difficult to establish that *Nkx5.1*-derived INs originate from progenitors residing in the POA ventricular zone (VZ). We have thus modified the manuscript accordingly and removed the term "progenitor" throughout the manuscript. We now indicate that *Nkx5.1*-derived INs are observed in the embryonic POA region but do not make the claim that they derive from progenitors generated in the POA VZ. Additional tools would be required to answer the specific question of their mitotic progenitor origin (see our fourth response).

> Are there Nkx5.1-tdTOM+/Htr3a(BAC)-EGFP cells that remain in the POA at postnatal ages? If so, it would be difficult to distinguish whether the double positive cells highlighted in [Figure 1A](#fig1){ref-type="fig"} give rise to the cortical interneurons analyzed vs. lineages that remain in the POA.

We have investigated postnatal ages, and observed that in contrast to the embryonic POA, only very few *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ cells remained postnatally in subpallial regions corresponding to embryonic POA region, such as the preoptic nuclei (PoN). This observation supports the hypothesis that embryonic double-labelled *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ cells exit the embryonic POA to populate other brain regions such as cortex. These new data are now provided in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} and are described in the new Results section.

> Because Nkx5.1 is not expressed in progenitors, the absence of overlap with Nkx2.1 ([Figure 1E](#fig1){ref-type="fig"}) does not prove that these lineages do not arise from an Nkx2.1+ territory; in fact, Flames et al. presented evidence (as does [Figure 1E](#fig1){ref-type="fig"}) that Nkx2.1 is expressed in the entire POA progenitor pool, even though Lhx6 expression is not maintained in POA lineages, in contrast to those arising from the MGE. Recent fate maps using an Nkx2.1-Flpo knock in line (vs. the Nkx2.1(BAC)-Cre, whose expression was known to be excluded from the Nkx6.2 territory) show little if any labeling of layer 1 -- this does not prove that layer 1 cells do not arise from the POA, but it puts more weight on the accuracy of the Nkx5.1(BAC)-Cre line as a proxy for POA origin. How do the fate maps in this study compare with those shown in Gelman et al. 2009? Has there been any \'drift\' in the recombination mediated by this BAC tg over time?

We agree with these interesting comments, which are also related to the sixth point below. It is true that the progenitors in the VZ of the POA region express high levels of *Nkx2.1* as shown in Flames et al. work (2007). Our new quantification at E14.5 in POA, indicates that only a small fraction (about 15%) of *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ cells co-express NKX2.1. As suggested by reviewers, it is thus possible that postmitotic cells from the *Nkx5.1* lineage downregulate *Nkx2.1* after exiting the VZ of the POA. However, it should be noted that the*Nkx2.1*-Flpo knock-in line does not appear to label cells in layer 1 (see Figure S1 in He et al., 2016), indicating that *Nkx5.1*-derived NGCs in layer 1 may derive from progenitors that do not belong to the *Nkx2.1* lineage.

To comment on this point, we have now added in the Discussion the following new paragraph with new references:

"In the embryonic POA, we observe that only a small fraction of *Nkx5.1*; tdTOM+ / *Htr3a*-GFP+ cells express the TF NKX2.1, which has been shown to be strongly expressed in the ventricular zone of the POA (Flames et al., 2007). \[...\] Overall, further work needs to be done to clarify the precise origin of mitotic progenitors giving rise to the pool of Nkx5.1; tdTOM+ / Htr3a-GFP+ cells observed in the embryonic POA."

Finally,although a drift in recombination of the BAC trangenics over time is always possible, the pattern of recombination we have observed appears quite similar to the Gelman et al. publication.

> There are tdTOM+/GFP+ cells in all layers of the neocortex, yet the authors have only characterised the electrophysiological properties of cells in layer 1. Are neurons in other layers also NGCs? Do they express Car4 and have the characteristic morphology of NGCs? A detailed characterization of these neurons throughout all layers is not expected, but it is important to clarify this point.

We analysed *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ INs in deeper cortical layers to determine whether they also displayed NGC characteristics. As for layer 1 cells, *Car4* expression was significantly higher in *Nkx5.1*; tdTOM+ / *Htr3a*-GFP+ INs residing in layer 2-6 as compared to *Htr3a*-GFP+ INs negative for tdTOM ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). Morphological reconstructions of *Nkx5.1*; tdTOM+ / *Htr3a*-GFP+ INs in layers 2-6 revealed that all cells had the characteristic morphology of NGCs with dense and fine axonal ramifications ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). Furthermore, electrophysiological recordings of *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ INs in cortical layers 2-6 indicated that they displayed a more pronounced tendency to late-spiking compared to layer 1 cells, an electrophysiological property which is a typical of NGCs ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). These new molecular, morphological and electrophysiological data comparing layer 1 and layer 2-6 *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ INs are available in [Figure 6---figure supplements 3](#fig6s3){ref-type="fig"}, 4 and in the [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}---source data 1 and 2.

> Quantifications are also needed for panels 1C-E.

These quantifications are now provided in the main [Figure 1](#fig1){ref-type="fig"} and in the Results section. Detailed cells counts are available in the [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.

> In relation to the expression of Nkx2-1, this transcription factor is downregulated as cells migrate towards the cortex (Nobrega-Pereira et al., 2008). Previous work that has suggested that NGCs derive from both the MGE and the CGE (Tricoire et al., J Neurosci 2010), so it would be important to determine in the tdTOM+/GFP+ cells studied here derive from Nkx2-1 progenitor cells in the POA. On that note, the authors should correct the statement that Nkx2-1 is an MGE-specific transcription factor. This is not correct: Nkx2-1 is also expressed in the ventricular zone of the POA \[Flames et al., 2007\]). The tdTOM+/GFP+ cells may downregulate Nkx2-1 by the time they have left the ventricular zone. This is a complicated experiment, because it would probably involve crossing Nkx2-1-Flp and Nkx5.1-Cre lines with a dual reported, but this is necessary to support the claim \"these results indicate that a fraction of Nkx5.1+ progenitors in the POA express 5-HT3AR and a pattern of TFs more related to CGE than to MGE-derived INs\".

We fully agree that further work needs to be done to clarify the precise origin of mitotic progenitors giving rise to *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ cells observed in the embryonic POA. As correctly mentioned by the reviewers this specific point can only be resolved by a complicated experiment involving additional transgenic mouse lines, including the Nkx2.1-Flpo knock-in line and a dual reporter mouse line. As indicated in our answer to point 1, we have modified the manuscript and now indicate that Nkx5.1-derived INs are observed in the embryonic POA region but do not make the claim that they derive from progenitors generated in the POA ventricular zone. In addition, we have added a new paragraph in the discussion to address this point (see our answer to point 3). Finally, have removed the statement that Nkx2.1 is a MGE-specific transcription factor.

> The authors should include morphological reconstructions of the axon of tdTOM+/GFP+ cells to reinforce the notion that these cells are indeed NGCs. The axon of these cells is so characteristic that is almost impossible to miss.

We now provide morphological reconstructions of *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ INs in layers 1-6. All reconstructed cells displayed the characteristic morphology of elongated NGCs with dense and fine axonal ramifications ([Figure 6](#fig6){ref-type="fig"}, [Figure 6 supplement 1](#fig6s1){ref-type="fig"}, [4](#fig6s4){ref-type="fig"}).

> Another interesting property of NGCs (at least in hippocampus and piriform cortex) is persistent firing that outlasts the injected current (Sheffield et al., Nature Neurosci 2011; Suzuki et al., Front Cell Neurosci 2014). Is this property also observed in S1 tdTOM+/GFP+ cells?

Although the physiological importance of persistent firing is not well understood, we agree that it is interesting to explore whether this property described for NGCs of the hippocampus and the piriform cortex also pertains to NGCs of the neocortex. In our first set of recordings to study the firing properties of *Nkx5.1*-derived NGCs in barrel cortex layer 1 (BC L1), we used protocols of 0.5 s-long subsequent depolarizing current steps with 20 pA increments (similarly to Sheffield et al., Nat Neurosci., 2011). This protocol did not trigger persistent firing in any of the 21 *Nkx5.1*-derived NGCs included in the analysis of our first submission. To verify that this was not merely due to our experimental conditions, we performed additional recordings from 6 *Nkx5.1*-derived NGCs in L1-3, using two different protocols for somatic stimulation described by Suzuki et al., (Front Cell Neurosci,2014) (1 s-long depolarizing current steps (0.5-1.5 nA) at 0.5 Hz, and 2 ms-long depolarizing current steps (1.0-1.5 nA) at 20 Hz). Persistent firing occurred only in 1 out of 6 recorded *Nkx5.1*-derived NGCs (17%), in the second trial of the 1 s-long depolarizing current steps protocol. It lasted for 6.5 s after the 20^th^ depolarizing current step and it did not reoccur in the following three trials of stimulation that took place with 2 min intervals. Our values for frequency of occurrence and duration (17% and 6.5 s respectively) were much lower as compared to the ones reported for NGCs by Suzuki et al., (Front Cell Neurosci, 2014). As reported in the above-mentioned studies, the range of temperature as well as the concentrations of K^+^ and Ca^2+^ in the recording ACSF are critical for persistent firing occurrence and duration. Most probably, the lower temperatures (30-32°C vs. 33-35°C) and the lower K^+^ concentration (2.5 mM vs. 3.0 mM) in our experiments account for the lower frequency of occurrence, whereas the higher Ca^2+^ concentration (2.5 mM vs. 2.0 mM) accounts for the shorter duration of persistent firing. Hence, we conclude that persistent firing can also be induced in *Nkx5.1*-derived NGCs in BC superficial layers, but its occurrence and duration depends strongly on the experimental conditions applied. It will be interesting to further investigate which conditions would allow a higher incidence and duration of persistent firing in these cells. However, we feel that this is beyond the scope of the present study.

> Additional experiments requested by reviewers but not essential. If not performed, at least address in the text:
>
> Since NGFCs have also been reported in other cortical layers, it would be good if the authors recorded the Htr3a-GFP and Nkx5.1-tdtomato positive fate-mapped cells in other layers besides layer 1. Although beyond the scope of the paper, it would also be very interesting to check the fate-mapped cells in other brain regions the cells have shown to be present, such as the amygdala. The study would be more complete if the authors morphologically reconstructed some cells from several layers (can be combined with point 1) to show that they fit the pattern observed in other studies.

As indicated in our response to point 4, we analysed *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ INs in deeper cortical layers to determine whether they also displayed NGC characteristics. As for layer 1 cells, *Car4* expression was significantly increased in *Nkx5.1*; tdTOM+ / *Htr3a*-GFP+ INs residing in layer 2-6 as compared to *Htr3a*-GFP+ INs negative for tdTOM ([Figure 6 supplement 3](#fig6s3){ref-type="fig"}). Morphological reconstructions of *Nkx5.1*; tdTOM+ / *Htr3a*-GFP+ IN residing in cortical layers 2-6 revealed that all cells had the characteristic morphology of NGCs with dense and fine axonal ramifications ([Figure 6 Supplement 4](#fig6s4){ref-type="fig"}). Furthermore, recordings of *Nkx5.1*; tdTOM+ / *Htr3a-*GFP+ INs in cortical layers 2-6 indicated that they displayed more pronounced NGC electrophysiological profiles such as late-spiking properties compared to layer 1 cells([Figure 6 Supplement 3](#fig6s3){ref-type="fig"}).

Finally, we have observed *Nkx5.1*; tdTOM+ / *Htr3a*-GFP+ fate-mapped cells in a variety of brain regions including the amygdala and hippocampus. These cells are now shown in illustrative rostro-caudal sections in a new [Figure 2 Supplement 1](#fig2s1){ref-type="fig"}

> Perform a limited number of paired-recordings between interneurons and pyramidal cells to show that the Htr3a-GFP and Nkx5.1-tdtomato positive cells have the very characteristic slow GABAA and GABAB receptor -dependent synaptic output of NGFCs and that Htr3a-GFP only cells do not. The reviewer does realize that this is a significant and time-consuming task, but if achieved, it would leave very little room for disputes on whether these cells are NGFCs.

Given that new molecular, morphological and electrophysiological recordings performed in other cortical layers confirm that *Nkx5.1*; tdTOM+ / *Htr3a*-GFP+ have characteristic features of NGCs, this specific point was not addressed.

[^1]: ^\*^contributed equally.

[^2]: These authors contributed equally to this work.
